• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Reed introduces bill to strengthen cancer research reporting requirements

Reed introduces bill to strengthen cancer research reporting requirements

May 4, 2012
CenterWatch Staff

Congressman Tom Reed has introduced legislation in the U.S. House of Representatives which strengthens the enforcement mechanisms of the requirement to publicly report results of cancer trials and research conducted with federal grant money. The goal of the legislation is greater sharing of cancer research results in the search for a cure to cancer.

"The more information available to all researchers, the greater the chance that we will someday find a cure for this horrible disease," Reed said. "Public reporting of both positive and negative results will help other research be more effective and less duplicative. Enforcing the reporting requirement will not only lead to more available cancer research data, but also help every taxpayer dollar spent on research go further toward finding a cure."

"We are so excited and thrilled that our Congressman Tom Reed is introducing legislation which is the result of input received at the Cancer Mission 2020 congressional district cancer summits held last summer," said Gary Mervis, chairman and founder of Camp Good Days and Special Times/Cancer Mission 2020. "This legislation is helping us to take a first step forward in our efforts to end cancer by the end of the decade."

Current law requires that the results of cancer research conducted with federal money be publicly reported. However, the enforcement mechanism is very weak and as a result not all of the cancer research conducted is reported. Reed's bill will require that any unreported research be penalized by forcing full repayment of the research grant to the Treasury. In addition, the recipient of the grant will be ineligible for future grants.

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing